Optimization of vancomycin administration in continuous renal replacement therapy

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100042393

Enrollment

Unknown

Registered

2021-01-21

Start date

2021-01-17

Completion date

Unknown

Last updated

2021-04-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Critical ill infection

Interventions

control group:Loading dose of vancomycin was 15-20mg/kg, maintenance dose was 0.5g,q24h-1.5g, q48h

intervention group:the daily dose of continuous intravenous infusion of vancomycin was calculated according to the calculation formula of clearance intensity of CVVH and clearance of vancomycin, and 1

Eligibility

Sex/Gender

All

Age

18 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. Patients with vancomycin empirical or targeted anti infective therapy; 2. Patients with acute renal failure caused by critical illness; 3. Patients with oliguria or anuria during CRRT; 4. Patients over 18 years old.

Exclusion criteria

Exclusion criteria: 1. Subjects with urine volume > 0.5ml/kg/h during CRRT; 2. Patients undergoing extracorporeal membrane oxygenation; 3. Other patients with non acute renal damage undergoing CRRT; 4. Subjects who are allergic to vancomycin or have serious adverse reactions.

Design outcomes

Primary

Measure	Time frame
Blood concentration of vancomycin;	—

Countries

China

Contacts

Public ContactTang Lian

Suzhou Hospital Affiliated to Nanjing Medical University

tanglian716@aliyun.com+86 15250491039

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 11, 2026